Solid Biosciences (SLDB) director receives 77,500 stock options at $6.61 exercise price

Rhea-AI Filing Summary

Solid Biosciences Inc. director Martin I. Freed received a grant of stock options covering 77,500 shares of common stock. The options have an exercise price of $6.61 per share and were awarded at no upfront cost as a compensation grant.

The option vests in full on the earlier of the one-year anniversary of the June 10, 2026 grant date or immediately before the company’s next annual meeting of stockholders after that date, and will fully vest on specified change in control events. Following this grant, Freed holds 77,500 stock options directly.

Insights

Equity Compensation Analyst

Routine director stock option grant aligns with standard board compensation.

Director Martin I. Freed received 77,500 stock options with a $6.61 exercise price, reflecting typical equity-based compensation rather than an open-market purchase. The options were granted at no cost and are structured to vest over a short service horizon.

The award vests on the earlier of the one-year anniversary of June 10, 2026 or immediately before the next annual stockholder meeting, and accelerates upon specified change in control events. This creates service- and event-based incentives without immediate cash impact, and is generally neutral from an investment thesis perspective.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Freed Martin I

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	77,500	$0.00	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 77,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 77,500 options Exercise price: $6.61 per share Post-transaction option holdings: 77,500 options +2 more

5 metrics

Options granted 77,500 options Director grant on June 10, 2026

Exercise price $6.61 per share Director stock option grant

Post-transaction option holdings 77,500 options Held directly after grant

Option expiration June 10, 2036 Expiration date of granted options

Transaction code A (grant/award acquisition) Form 4 derivative transaction type

Key Terms

Director Stock Option (Right to Buy), exercise price, vests in full, annual meeting of stockholders, +1 more

5 terms

Director Stock Option (Right to Buy) financial

"security_title: Director Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 6.6100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in full financial

"This option was granted on June 10, 2026 and vests in full on the earlier"

annual meeting of stockholders regulatory

"earlier to occur of the one-year anniversary and immediately prior to the Issuer's next annual meeting of stockholders"

change in control events financial

"will vest automatically as to 100% of the unvested portion upon specified change in control events"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Freed Martin I

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MASSACHUSETTS 02129

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$6.61	06/10/2026		A		77,500		(1)	06/10/2036	Common Stock	77,500	$0.00	77,500	D

Explanation of Responses:

1. This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

	/s/ Kimberly Cornwell as attorney-in-fact for Martin I. Freed	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Solid Biosciences (SLDB) report for Martin I. Freed?

Solid Biosciences reported that director Martin I. Freed received a grant of 77,500 stock options. These options give him the right to buy common shares at a fixed exercise price as part of his equity compensation, rather than being an open-market purchase or sale.

How many stock options did the Solid Biosciences director receive in this Form 4?

Director Martin I. Freed received 77,500 stock options. Each option represents the right to acquire one share of Solid Biosciences common stock, bringing his total direct option holdings reported in this filing to 77,500 after the grant was made.

What is the exercise price of the new Solid Biosciences (SLDB) stock options?

The granted options have an exercise price of $6.61 per share. This means Freed can buy Solid Biosciences common stock at $6.61 under the option terms, regardless of the market price when he eventually exercises, if the options are vested and unexpired.

When do Martin I. Freed’s newly granted Solid Biosciences options vest?

The options vest in full on the earlier of the one-year anniversary of the June 10, 2026 grant date or immediately prior to Solid Biosciences’ next annual stockholder meeting. They also fully vest upon specified change in control events, according to the footnote disclosure.

Is the Solid Biosciences Form 4 transaction a buy or a grant of options?

The Form 4 reports a grant of stock options, not an open-market buy. The transaction code is “A” for a grant or award acquisition, meaning Freed received the options as compensation rather than purchasing shares directly on the market.

How many Solid Biosciences options does Martin I. Freed hold after this transaction?

After the June 10, 2026 grant, Martin I. Freed holds 77,500 stock options directly. The filing’s post-transaction holding figure matches the size of the new award, indicating this grant accounts for his reported derivative holdings in this specific Form 4.